Introduction {#s1}
============

Very different pathologies, such as cardiovascular disease, malaria, and tumor metastasis, share a mechanism involving the membrane glycoprotein CD36. It was first identified as an adhesion protein, mediating collagen, fibronectin, thrombospondin (TSP) ([@B106]; [@B98]), and *Plasmodium falciparum* binding ([@B9]). CD36 was later demonstrated to be a scavenger receptor ([@B35]; [@B98]), a fatty acid translocator for native and oxidized low-density lipoprotein (oxLDL) ([@B34]), anionic phospholipids ([@B95]), and long-chain fatty acids (FAs) ([@B2]; [@B41]). These different functions are performed by different binding sites of the extracellular domain of the receptor ([@B7]; [@B52]), and the outcome of ligand binding is largely dependent on cell type. In muscle, adipose, and intestinal cells, CD36 participates mainly in lipid uptake ([@B99]; [@B109]).

In macrophages, depending on the environment, CD36 can act as a scavenger of oxLDL, forming foam cells ([@B78]) as a pattern recognition receptor, in innate immunity ([@B108]), or as a trigger of inflammatory responses ([@B103]; [@B89]). In endothelial cells, it has mainly anti-angiogenic and pro-apoptotic effects *via* thrombospondin binding ([@B59]). In vascular smooth muscle cells, CD36 may contribute to generation of reactive oxygen species (ROS) and cellular proliferation ([@B65]; [@B124]). In sensory cells, it can act as a taste ([@B62]; [@B55]; [@B81]; [@B76]) or olfactory receptor ([@B75]; [@B119]).

CD36 is currently investigated as a potential therapeutic target in cardiovascular disease ([@B86]), metabolic syndrome, and obesity ([@B23]; [@B43]). Several preclinical ([@B79]; [@B61]; [@B101]) and clinical studies ([@B66]; [@B77]) recently demonstrated that upregulation of CD36 could be a prerequisite for tumor metastasis (reviewed in [@B33]), opening new avenues for anticancer therapies. Even though the localization and changes in expression of CD36 protein have been sufficiently addressed, less is known about how epigenetic and post-transcriptional regulation of CD36 influences CD36-related pathologies. A more detailed look into these less explored areas is necessary to highlight gaps in knowledge, as well as new possible therapeutic targets. Therefore, the aim of this review was to summarize major epigenetic and post-transcriptional mechanisms with impact on CD36 expression in relation to various pathologies. The blank spots on the CD36 map are also addressed.

CD36 Gene Regulation and Gene-Related Pathologies {#s1_1}
-------------------------------------------------

The CD36 gene is located on the long arm of chromosome 7 (7q21.11) (*Homo sapiens* Annotation Release 109, GRCh38.p12) and consists of 17 exons and 18 introns and can generate four protein isoforms *via* alternative splicing (<https://www.ncbi.nlm.nih.gov/gene/948>). Out of the four isoforms, three have at least one spliced exon (4, 6-7, or 8) (UniProtkB ID: P16671). At least 23 alternative transcripts are known for CD36, and six alternative first exons have been described, yielding different transcripts in different tissue types ([@B84]; [@B72]). A STAT binding GAS element has also been identified in the CD36 gene promoter ([@B101]), and several papers have reported that CD36 expression is modulated by various STAT family members ([@B47]; [@B60]; [@B96]).

Gene promoter translation is under the control of core binding factor (CBF) family members ([@B6]) and CCAAT/enhancer-binding protein α (C/EBPα) ([@B88]). A major regulator of *CD36* expression is peroxisome proliferator activated receptor gamma (PPAR-γ), which binds to enhancer regions of *CD36* ([@B72]), but other transcription factors, such as Activating Transcription Factor 2 (ATF2), were demonstrated to induce CD36 expression as well ([@B91]). Genetic modifications of *CD36* have been investigated thoroughly since the identification of malaria-predisposing mutations ([@B3]). More than 9,000 SNPs have been described in the CD36 gene, in both intronic and exonic sequences, as well as the 5′ and 3′ untranslated regions (UTRs), but only a handful of them have been associated to known pathologies (<https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD36#transcripts>). This is due in part to the large blocks of linkage disequilibrium across the gene in several of these population studies. CD36 polymorphisms are more frequent in Asian and African American populations than Caucasians ([@B68]). Several studies have investigated CD36 polymorphism in African Americans ([@B68]; [@B11]) and genome wide studies comparing other ethnic groups ([@B22]; [@B32]). A gene-centric meta-analysis of lipid traits in African, East Asian, and Hispanic populations confirmed previous data on CD36 polymorphisms and proposed the rs3211938-G allele, which is nearly absent in European and Asian populations, as a "signature of selection" in Africans and African Americans ([@B31]).

Regarding copy number variations (CNVs), *CD36*-related modifications occur mostly with loss of genetic sequences ([@B114]; [@B104]; [@B111]), leading to platelet glycoprotein IV deficiency or neurocognitive developmental delay ([@B20]).

In addition to genetic alterations, epigenetic and post-transcriptional interventions can also modify the final protein output, impacting protein function. Gene expression can be further altered in the cytoplasmic compartment by non-coding RNA species that can interfere with mRNA translation and modulate protein output ([@B85]). Some of these epigenetic gene control mechanisms are addressed below with respect to CD36 expression and involvement in pathology. Post-translational modifications of CD36 were reviewed recently by [@B69] and are beyond the scope of this review.

Epigenetic Regulation {#s1_2}
---------------------

Epigenetics is defined as "the study of changes in gene function that are mitotically and/or meiotically heritable and that do not entail change in DNA sequence" ([@B118]). Although no general consensus has been reached in regard to which mechanisms can be categorized as epigenetic ([@B27]), they usually involve nuclear processes, such as DNA methylation, histone modifications, and non-coding RNAs ([@B42]; [@B82]; [@B92]).

DNA methylation involves the transfer of methyl groups from S-adenosylmethionine to cytosines in CpG dinucleotide sequences. The methylation patterns of CpG sites are created and maintained by a family of DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) and can be reversed by ten-eleven translocation (TET) enzymes ([@B74]; [@B83]). Hypermethylation is associated with gene repression, and hypomethylation with gene activation ([@B73]). Alterations of methylation patterns play an important part in regulating gene activity during embryogenesis, gametogenesis, and cellular differentiation ([@B42]; [@B83]). In many types of cancer, global hypomethylation has been observed at repetitive genomic regions, leading to genomic instability, in combination with hypermethylation at specific CpG-rich islands in the promoters of key tumor suppressor genes ([@B83]; [@B73]; [@B107]; [@B92]).

Histone (H) proteins organize chromatin into structural units called nucleosomes, which consist of DNA wrapped around an octamer of H2A, H2B, H3, and H4 core histones connected by linker DNA and stabilized by H1 ([@B46]). Epigenetic events usually include covalent modification of amino acids from the H3 and H4 tails ([@B17]; [@B51]; [@B74]). These changes represent the so-called "histone code," which affects the conformation of the chromatin fiber, regulating the switch between euchromatin (transcriptionally active) and heterochromatin (transcriptionally inactive) ([@B74]). Histone modifications are mediated by histone acetyltransferases (HATs), histone deacetylases (HDACs), histone methyltransferases (HMTs), and polycomb repressive complex 2 (PRC2) ([@B74]; [@B107]). Several studies have shown an interplay between DNA methylation and histone modifications in determining the transcriptional status of a gene ([@B38]; [@B54]; [@B39]; [@B116]; [@B17]).

Non-coding RNAs (ncRNAs) are transcribed from DNA but not translated into proteins. Although not all categories of ncRNAs can be classified as epigenetic factors, several types have been shown to control epigenetic mechanisms and, in turn, to be regulated by the epigenetic machinery ([@B42]; [@B51]; [@B21]; [@B82]; [@B92]). The classes of ncRNAs that are epigenetically related are long non-coding RNAs (lncRNAs) and three types of short non-coding RNAs: microRNAs (miRNAs), short interfering RNAs (siRNAs), and Piwi-interacting RNAs (piRNAs) ([@B21]; [@B82]). However, the data available on CD36 regulation by ncRNAs show an involvement of the latter only in post-transcriptional mechanisms controlling CD36 mRNA levels, with no input from the epigenetic machinery.

### DNA Methylation of *CD36* {#s1_2_1}

The human CD36 gene presents several promoter sequences and distal cis-regulatory elements, which contain a number of CpG sites ([@B72]). Changes in CpG methylation patterns in the *CD36* promoters have been studied more extensively in relation to lipid metabolism and associated disorders. One study investigated the impact of *CD36* promoter SNPs and DNA methylation sites on postprandial lipid uptake and clearance in adipose and heart tissue ([@B67]). Several SNPs were associated with higher chylomicron (CM) remnants and LDL particle numbers, as well as a delayed triglyceride (TG) clearance, and some of them also correlated with lower CD36 mRNA levels and aligned to binding sites for PPAR-γ. Furthermore, the SNPs negatively related to CD36 level were associated with methylation at several CpG sites, although the two factors seem to function independently in regulating *CD36* mRNA expression ([@B67]).

Several studies have focused on obesity and its related co-morbidities: metabolic syndrome or obesity hypoventilation syndrome. In a weight loss and n-3 polyunsaturated fatty acid (PUFA) supplementation study in young overweight women, *CD36* promoter methylation was significantly reduced when adjusted for baseline body weight ([@B5]). *CD36* was hypermethylated and less expressed in abdominal omental visceral adipose tissue (OVAT) from non-obese individuals than obese individuals ([@B56]). Fat deposits in OVAT have been shown to more strongly correlate with a higher risk of obesity-related co-morbidities than subcutaneous deposits ([@B113]). *CD36* hypermethylation has also been found in monocytes from patients with obesity hypoventilation syndrome, following the application of positive airway pressure during sleep (the current treatment for the condition) ([@B25]). Another study investigated the methylation of the most significant TG-associated CpG in a regulatory region within *CD36* ([@B4]): expression of the main CD36 transcript in adipose tissue from obese individuals with or without metabolic syndrome was negatively associated with methylation of this regulatory region.

DNA methylation profile of *CD36* has also been investigated in liver tissue. In human primary hepatocytes, *CD36* was hypomethylated and upregulated after 5 days of valproic acid (VPA) exposure, a HDAC inhibitor, which can also modulate the expression and DNA methylation level of genes involved in liver steatosis ([@B112]). [@B123] reported that *CD36* hypermethylation was induced in the livers of adult offspring mice by a high-lipid, high-energy maternal diet during gestation and lactation.

In addition to metabolic diseases, CD36 can be involved in the occurrence of cancer. Only one study has focused on the DNA methylation status of *CD36* in relation to tumor progression. [@B105] have reported a hypermethylation of *CD36*, correlated with low expression in primary lung tumors. CD36 inhibited migration, invasion, and proliferation of lung cancer cells and arrested cell cycles in G0/G1 phase. Furthermore, treatment with decitabine, an inhibitor of DNA methylation and chidamide, an HDAC inhibitor, decreased the methylation and increased the mRNA expression level of *CD36*.

Currently, most of the data regarding changes in *CD36* DNA methylation come from genome-wide or epigenome-wide studies focusing on obesity and metabolic disorders, such as diabetes. The different DNA methylation signatures found in adipose tissue from lean vs. obese individuals with or without metabolic disorders could be investigated further to establish the causality between these epigenetic variants and associated pathologies. An overlooked area of research is the involvement of *CD36* methylation in the onset of cancer.

A summary of DNA methylation changes affecting the CD36 gene is presented in [**Table 1**](#T1){ref-type="table"}.

###### 

*CD36* epigenetic changes based on cell type/tissue.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of modification                                    Tissue/cell type                                                                               Effect                                    References
  ------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------- ------------------------
  ***DNA methylation***                                                                                                                                                                            

  CpG methylation                                         Adipose and heart tissue                                                                       Decreased *CD36* mRNA                     [@B67]

  Adipose tissue                                          Downregulation of protein expression                                                           [@B4]                                     

  Hypermethylation                                        Omental visceral adipose tissue (non-obese individuals)                                        Reduced protein expression                [@B56]

  Monocytes (obesity hypoventilation syndrome patients)   Reduced protein expression, reduced inflammation                                               [@B25]                                    

  Hepatocytes                                             Upregulation, increased FA influx from peripheral tissue                                       [@B112]                                   

  Lung tumors                                             Low protein expression, increased migration, proliferation and invasion of lung cancer cells   [@B105]                                   

  ***Histone methylation***                                                                                                                                                                        

  H3K4me3\                                                Erythroid precursors CD36+\                                                                    Differentiation to erythroid precursors   [@B26]; [@B72]; [@B10]
  increased                                               Adipocytes\                                                                                                                              
                                                          Monocytes                                                                                                                                

  H3K4me1, H3K9me1, H3K36me, H4K20me1                     Erythroid precursors CD36+                                                                     Differentiation to erythroid precursors   [@B26]

  ***Histone acetylation***                                                                                                                                                                        

  H3K9Ac                                                  Aortic macrophages subjected to chronic intermittent hypoxia                                   Increased *CD36* mRNA expression          [@B24]

  H3K27Ac                                                 Adipocytes                                                                                     Open chromatin                            [@B72]

  H4 acetylation                                          Macrophages                                                                                    Increased *CD36* mRNA                     [@B18]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Histone Modifications of *CD36* {#s1_2_2}

The CD36 gene promoters and distal enhancers that bind CCCTC-binding factor (CTCF) or PPAR-γ are subjected to both histone acetylation and methylation ([@B72]). Although histone tails can be subjected to many other covalent modifications, they have not been documented in CD36 expression. Changes in *CD36* histone marks have been studied mostly in adipocytes ([@B102]; [@B72]), monocytes/macrophages ([@B18]; [@B10]; [@B24]), and hepatocytes ([@B13]; [@B127]), but also in erythroid precursors ([@B26]), fibroblasts ([@B40]), endothelial cells ([@B94]), and microglia ([@B120]). A summary of histone modifications affecting *CD36* is presented in [**Table 1**](#T1){ref-type="table"}.

Gene expression of *CD36* in human adipocytes has been shown to be activated by both H3K4me3 at P3, the major *CD36* promoter, and H3K27Ac in PPAR-γ enhancer ([@B72]). Intergenic enrichment of H3K79 monomethylation upstream of *CD36* correlates with PPAR occupancy ([@B102]). The H3K4me3 mark at the *CD36* promoter has also been linked to differentiation of hematopoietic stem/progenitor cells to erythroid precursors ([@B26]), and in macrophages it accompanies the switch to a pro-inflammatory phenotype ([@B10]). Another histone mark affecting CD36 expression in macrophages is H3K9Ac enrichment, which is found in aortic macrophages exposed to long-term chronic intermittent hypoxia, resulting in a higher *CD36* mRNA level ([@B24]). Increased H3 acetylation upstream of the *CD36* promoter has also been correlated with hepatic accumulation of TGs ([@B13]).

Activation or repression of *CD36* expression *via* histone modifications can be induced pharmacologically. Using trichostatin A (TSA), a specific HDAC inhibitor, that stimulates acetylation of H4 at the *CD36* promoter, increases *CD36* mRNA, followed by higher uptake of oxLDL in macrophages ([@B18]). CD36 repression has been reported with lysophosphatidic acid, *via* HDAC7 in endothelial cells ([@B94]), and an HDAC3 inhibitor (RGFP966) in primary microglia ([@B120]).

Two studies have shown that the relationship between CD36 and histone modifiers is not unidirectional, and the former is capable of influencing the activity of the latter. [@B127] reported that *CD36* deletion inhibits nuclear HDAC2 expression in hepatocytes, changing the acetylation of histones binding to the monocyte chemoattractant protein-1 (MCP-1) promoters and increasing macrophage infiltration and hepatic inflammation. In a study investigating the efficiency of VPA treatment in patients with spinal muscular atrophy, non-responsiveness to the drug was linked to CD36 overexpression, which suppressed the inhibitory effect of VPA on HDACs ([@B40]).

*CD36* histone modifications affect cells involved in lipid metabolism, but in contrast to DNA methylation patterns, changes in *CD36* histone marks in these cells have been associated mostly with inflammation ([@B10]; [@B127]). Several studies activating or inhibiting CD36 *via* histone modifiers have shown the therapeutic potential of these histone marks as targets for regulating the inflammatory response ([@B10]; [@B127]). Although histone modifications have been documented extensively in cancer ([@B8]), no study has yet linked *CD36* histone marks with tumorigenesis.

Post-Transcriptional Regulation {#s1_3}
-------------------------------

miRNAs are small single-stranded RNA molecules (18--25 nucleotides) ([@B97]; [@B74]) that start off as long primary miRNA transcripts (pri-miRNAs), generated by RNA polymerase II. They are cleaved into hairpin precursors (pre-miRNAs) in the nucleus by a complex containing the RNAse III Drosha ([@B97]; [@B74]), exported to the cytoplasm, and further cleaved into miRNA duplexes by RNAse III Dicer ([@B97]; [@B74]). One of the RNA strands is incorporated into the RNA-induced silencing complex (RISC) and drives its binding to the 3′-UTR of the target mRNA, where it induces cleavage and degradation or translational repression ([@B21]; [@B97]; [@B74]). miRNA expression can be regulated by epigenetic mechanisms ([@B110]; [@B74]). miRNAs themselves can control the epigenetic machinery by modulating the activity of various epigenetic effectors at a post-transcriptional level in the cytoplasm. However, miRNAs can also act in the nucleus at the transcriptional level, activating or repressing gene transcription by inducing changes in the chromatin state ([@B74]; [@B92]).

lncRNAs are non-protein-coding transcripts longer than 200 nucleotides with higher tissue specificity than protein-coding genes ([@B73]). Through interaction with other molecules (proteins, DNA, other RNAs), lncRNAs can regulate gene expression at transcriptional and post-transcriptional levels and direct epigenetic changes by coordinating chromatin remodeling, affecting DNA methylation, or acting as competing endogenous RNAs by binding to the target sequence of miRNAs ([@B37]; [@B73]; [@B45]; [@B48]).

### CD36 Regulation by miRNAs {#s1_3_1}

*CD36* mRNA is targeted by different species of miRNA that modulate its expression at a post-transcriptional level in a tissue-specific manner. [**Table 2**](#T2){ref-type="table"} summarizes the species of ncRNAs (miRNAs and lncRNAs) demonstrated to be involved in the regulation of CD36 expression. [@B128] reported that CD36 is increased during bone marrow cell differentiation towards the monocytic-macrophage line and associated with differential expression of seven miRNA species; miR-130a, -134, -141, -199a, and -363 were decreased, and miR-152 and -342-3p were increased. The miR expression profiling in erythropoiesis revealed that miR-16, miR-22, miR-26a, and miR-223 correlated with the appearance and level of CD36 as an erythroid surface antigen ([@B19]).

###### 

Post-transcriptional regulation of CD36 and functional/pathological significance by cell type.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Non-coding RNA     Effect on *CD36* mRNA   Cell type                                            Functional/pathological significance                                   References
  ------------------ ----------------------- ---------------------------------------------------- ---------------------------------------------------------------------- ------------
  ***miRNAs***                                                                                                                                                           

  miR-16\            Upregulation            Erythroid cells                                      CD36 erythroid surface antigen appearance                              [@B19]
  miR-22\                                                                                                                                                                
  miR-26a                                                                                                                                                                

  miR-26a/b          Downregulation          Kidney cells (cortex)                                Hypertension                                                           [@B71]

  miR-27a            Downregulation          Pre-adipocytes                                       Negative regulator of adipocyte differentiation                        [@B58]

  miR-27a/b          Downregulation          Macrophages                                          Blocking of lipid uptake                                               [@B125]

  miR-29a            Upregulation            oxLDL-stimulated dendritic cells                     Increased lipid uptake                                                 [@B16]

  miR-34a            Downregulation          White adipocytes                                     Reduced lipid uptake                                                   [@B63]

  miR-130a           Downregulation          Macrophages                                          Macrophage differentiation                                             [@B128]

  miR-133a           Downregulation          Macrophages                                          Reduced lipid accumulation                                             [@B80]

  miR-134            Downregulation          Macrophages                                          Macrophage differentiation                                             [@B128]

  miR-135a           Downregulation          Macrophages                                          Inhibition of foam cell formation; decreased TG, TC levels             [@B29]

  miR-141            Downregulation          Macrophages                                          Macrophage differentiation                                             [@B128]

  miR-152            Upregulation            Macrophages                                          Macrophage differentiation                                             [@B128]

  miR-155            Upregulation            oxLDL-stimulated macrophages                         Differentiation into dendritic cells                                   [@B70]

  miR-155            Downregulation          Macrophages, liver cells                             Reduced lipid uptake                                                   [@B36]

  miR-181a           Downregulation          Macrophages                                          Inhibition of foam cell formation; decreased TG, TC levels             [@B30]

  miR-182-5p         Downregulation          Macrophages                                          Reduced TG, TC levels; repression of ox-LDL induced apoptosis          [@B90]

  miR-199a           Downregulation          Macrophages                                          Macrophage differentiation                                             [@B128]

  miR-223            Upregulation            Erythroid cells                                      CD36 erythroid surface antigen appearance                              [@B19]

  miR-342-3p         Upregulation            Macrophages                                          Macrophage differentiation                                             [@B128]

  miR-363            Downregulation          Macrophages                                          Macrophage differentiation                                             [@B128]

  miR-590            Downregulation          Peritoneal macrophages from apoE^−/−^ mice           Suppressed lipoprotein lipase levels                                   [@B28]

  miR-758-5p         Downregulation          Macrophages                                          Reduced lipid accumulation                                             [@B64]

  ***lncRNAs***                                                                                                                                                          

  E330013P06         Upregulation            Macrophages                                          Increased uptake of modified LDL, promotion of foam cell formation     [@B93]

  MALAT1             Upregulation            Macrophages                                          Increased lipid uptake                                                 [@B50]

  n341587, n382000   Upregulation            Peripheral blood cells of type 2 diabetes patients   Insulin resistance, hyperinsulinemia                                   [@B115]

  NEAT1              Downregulation          Macrophages                                          Reduced lipid uptake by stabilizing *CD36* mRNA in paraspeckles        [@B49]

  uc.372             Upregulation            Hepatocytes                                          Enhanced lipid uptake by relieving miR-4668 suppression of CD36 gene   [@B44]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Given the association of CD36 with lipid metabolism and the robust expression on circulating monocytes and tissue macrophages, a lot of data have been collected from *in vitro* models using these cells. For example, in an *in vitro* atherosclerosis model based on oxLDL-stimulated dendritic cells derived from circulating monocytes, [@B16] found that increased levels of miR-29a were associated with higher expression of CD36 at both the protein and mRNA level. miR-155 induced expression of CD36 in oxLDL-treated macrophages, which promoted their differentiation into dendritic cells (DCs) ([@B100]). In addition, silencing miR-155 in a human monocytic-macrophage cell line upregulated the expression of CD36 and increased the uptake of lipids induced by oxLDL. CD36 and scavenger receptor A (SRA) have been shown to be involved in oxLDL-mediated miR-155 upregulation in DCs ([@B121]).

Several other studies have reported post-transcriptional regulation of this fatty-acid translocator by miRNAs. miR-758-5p was shown to specifically bind to the 3′-UTR of *CD36* mRNA, downregulating both the mRNA and protein in macrophages ([@B64]). Furthermore, these biochemical alterations were specifically related to reduced cellular cholesterol uptake. miR-34a is also involved in downregulation of CD36, as miR34a^−/−^ mice exhibit increased protein expression and increased lipid content in adipocytes ([@B63]). Other miRNA species involved in downregulation of CD36 are miR-135a ([@B29]), miR-181a ([@B30]), and miR-182-5p ([@B90]).

As with histone modifiers, interactions between CD36 and miRNAs can go both ways. For example, oxLDL binding to CD36 suppresses cellular Dicer levels and subsequent miR-30c-5p expression ([@B14]). In human prostate cancer cells, CD36 activation *via* TSP-2 binding downregulates miR-376c *via* a MAPK-dependent pathway ([@B15]).

Apart from several miRs that control the exposure of CD36 on the surface of erythroid precursors, most miRs species that have been shown to influence CD36 expression are involved in regulating lipid metabolism. For example, miR-133a attenuates lipid accumulation *via* the testicular orphan nuclear receptor 4 (TR4)-CD36 pathway in macrophages and may serve as a potential biomarker and potent therapeutic agent for atherosclerosis ([@B80]). On the other hand, CD36 is downregulated in hypertensive kidney (cortex), putatively targeted by miR-26a/b ([@B71]).

Despite insufficient evidence to support the clinical use of these miRs as potential diagnostic or prognostic biomarkers, further data could lead to their clinical relevance.

### CD36 Regulation by lncRNAs {#s1_3_2}

Fewer studies have investigated the roles of various lncRNAs in controlling CD36 expression, and they focus mainly on lipid uptake in macrophages. Two recent papers have demonstrated the involvement of lncRNAs metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) ([@B50]) and nuclear-enriched abundant transcript 1 (NEAT1) ([@B49]) in oxLDL-induced CD36-mediated lipid uptake by macrophages, which plays an important role in the development of atherosclerosis. MALAT1 was first identified in non-small cell lung cancer patients ([@B53]) but has been shown to be expressed in almost all human tissues ([@B126]). Although MALAT1 and NEAT1 loci are adjacent in the genome, their nuclear localization is distinct: MALAT1 is found in nuclear speckles, nuclear bodies that contain various pre-mRNA splicing factors, whereas NEAT1 is localized in paraspeckles, subnuclear structures present in the interchromatin space near the nuclear speckles ([@B117]). [@B50] show that oxLDL promotes MALAT1 transcription, which induces CD36 upregulation by binding to β-catenin and promoting its accumulation on PPAR-γ responding sites of the *CD36* promoter. Even though MALAT1 is known to act in epigenetic events, such as histone modification induced by an interaction with complexes PRC1 and PRC2 ([@B122]; [@B1]; [@B87]; [@B57]; [@B12]), it is not clear whether *CD36* transcription is affected by direct binding of the lncRNA to the promoter or by changing the nucleosome organization. oxLDL upregulates both NEAT1 isoforms (NEAT1 and NEAT1_2) and also stimulates NEAT1_2-mediated paraspeckle formation, which then suppresses lipid uptake by stabilizing *CD36* mRNA in paraspeckles ([@B49]).

CD36 upregulation was induced by overexpression of lncRNA E330013P06 in macrophages from diabetic mice ([@B93]), increasing foam cell formation and contributing to an enhanced inflammatory and atherogenic phenotype in macrophages. The human equivalent of lncRNA E33, MIR143HG, which has similar genomic organization as the mouse gene, was also overexpressed in monocytes from patients with type 2 diabetes ([@B93]). In another study focusing on aberrantly expressed lncRNAs in patients with type 2 diabetes, *CD36* mRNA expression had a high correlation coefficient with two co-expressed lncRNAs (NONCODE IDs n382000 and n341587) ([@B115]), demonstrating a possible role in the pathogenesis of type 2 diabetes through regulation of inflammation.

Finally, CD36 expression and that of other genes involved in lipid synthesis and uptake can be controlled by the interaction between an ultraconserved (uc) lncRNA and two species of miRs ([@B44]). The upregulation of uc.372 drives hepatic steatosis in mice, as well as patients with non-alcoholic fatty liver disease (NAFLD), by intervening in the maturation of miR-195 and miR-4668. In the case of *CD36*, uc.372 binds to the terminal loop region of pri-miR-4668, blocking its maturation and relieving its gene silencing effect on *CD36*. Because uc.372 promotes hepatic steatosis through these mechanisms, uc.372 inhibitors could be potential therapeutic agents for NAFLD.

Conclusions {#s2}
===========

CD36 is a widespread protein with various functions depending on tissue localization, from adhesion protein to scavenger for oxidized phospholipids and lipoproteins, or fatty acid translocator. CD36 is involved in cardiovascular and metabolic diseases, as well as immune responses and cancer metastasis. However, CD36 has been studied in detail in some cells (monocytes-macrophages) and diseases (obesity, atherosclerosis/cardiovascular diseases), whereas other areas (tumor metastasis) are less covered. Genetic mutations in *CD36*, and changes in protein expression have been repeatedly reported in relation to cardiac artery disease, metabolic syndrome and obesity, malaria, and tumor spreading. Beyond genetic variants of *CD36*, epigenetic and post-transcriptional controls of *CD36* gene expression play a significant role in protein function and may serve as regulatory circuits, which are yet insufficiently explored. DNA methylation of *CD36* has been studied mostly in relation to lipid metabolism and obesity, whereas changes in *CD36* histone marks have been linked to inflammation. Both epigenetic mechanisms can serve as targets for drug development in their associated pathologies. Thus far, a clear relationship has been demonstrated between certain miRNAs, CD36, and altered lipid profile that can be further exploited therapeutically. However, miRNAs do not stand alone in this post-transcriptional regulation, as long-noncoding RNAs are also responsible for the stability of *CD36* mRNA. No data are yet available on the involvement of other small non-coding RNA species in CD36 expression, such as endogenous siRNAs or piRNAs. Thus, in terms of epigenetic control of CD36, there are still many gaps to be filled, especially in cancer research.

Author Contributions {#s3}
====================

C-MN, A-ME, and MH gathered the data and wrote the manuscript; MH corrected the final proof. All authors have read and approved the submitted form.

Funding {#s4}
=======

This manuscript was funded by the Ministry of Research and Innovation in Romania, under Program 1---The Improvement of the National System of Research and Development, Subprogram 1.2---Institutional Excellence---Projects of Excellence Funding in RDI, Contract No. 7PFE/16.10.2018 and grant COP A 1.2.3., ID: P_40_197/2016.

Conflict of Interest Statement {#s5}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This manuscript was funded by the Ministry of Research and Innovation in Romania, under Program 1---The Improvement of the National System of Research and Development, Subprogram 1.2---Institutional Excellence---Projects of Excellence Funding in RDI, Contract No. 7PFE/16.10.2018 and grant COP A 1.2.3., ID: P_40_197/2016.

[^1]: Edited by: Chandravanu Dash, Meharry Medical College, United States

[^2]: Reviewed by: Laelie Allison Snook, University of Guelph, Canada; Nikhlesh Singh, University of Tennessee Health Science Center (UTHSC), United States

[^3]: This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of the journal Frontiers in Genetics

[^4]: †These authors have contributed equally to this work.
